JP6768527B2 - Ｇｄｆ１５調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療 - Google Patents

Ｇｄｆ１５調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療 Download PDF

Info

Publication number
JP6768527B2
JP6768527B2 JP2016573762A JP2016573762A JP6768527B2 JP 6768527 B2 JP6768527 B2 JP 6768527B2 JP 2016573762 A JP2016573762 A JP 2016573762A JP 2016573762 A JP2016573762 A JP 2016573762A JP 6768527 B2 JP6768527 B2 JP 6768527B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016573762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519764A5 (enExample
JP2017519764A (ja
Inventor
ジュリス，ジェノ
ラーナー，ロレーナ
Original Assignee
アベオ ファーマシューティカルズ， インコーポレイテッド
アベオ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベオ ファーマシューティカルズ， インコーポレイテッド, アベオ ファーマシューティカルズ， インコーポレイテッド filed Critical アベオ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2017519764A publication Critical patent/JP2017519764A/ja
Publication of JP2017519764A5 publication Critical patent/JP2017519764A5/ja
Application granted granted Critical
Publication of JP6768527B2 publication Critical patent/JP6768527B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016573762A 2014-06-20 2015-06-19 Ｇｄｆ１５調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療 Active JP6768527B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015242P 2014-06-20 2014-06-20
US62/015,242 2014-06-20
PCT/US2015/036794 WO2015196145A1 (en) 2014-06-20 2015-06-19 Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator

Publications (3)

Publication Number Publication Date
JP2017519764A JP2017519764A (ja) 2017-07-20
JP2017519764A5 JP2017519764A5 (enExample) 2018-07-26
JP6768527B2 true JP6768527B2 (ja) 2020-10-14

Family

ID=53724443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016573762A Active JP6768527B2 (ja) 2014-06-20 2015-06-19 Ｇｄｆ１５調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療

Country Status (8)

Country Link
US (2) US20170137506A1 (enExample)
EP (1) EP3157953B1 (enExample)
JP (1) JP6768527B2 (enExample)
AU (2) AU2015276800B2 (enExample)
CA (1) CA2952032C (enExample)
EA (1) EA201790051A1 (enExample)
MX (1) MX2016016826A (enExample)
WO (1) WO2015196145A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100689A1 (en) 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
WO2017109706A1 (en) * 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP4006049A1 (en) * 2016-01-29 2022-06-01 Washington University Gdf15 in glaucoma and methods of use thereof
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5733254A (en) 1987-10-15 1998-03-31 Cypress Bioscience, Inc. Method for treating patients suffering from immune thrombocytopenic purpura
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
AU2002257420A1 (en) 2001-05-01 2002-11-11 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
ES2555956T3 (es) * 2004-04-13 2016-01-11 St Vincent's Hospital Sydney Limited Método para modular el apetito
WO2009021293A1 (en) 2007-08-16 2009-02-19 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
CN101951921A (zh) 2007-09-17 2011-01-19 比奥尼里斯有限责任公司 用于治疗恶病质的方法和手段
JP2011502106A (ja) * 2007-10-09 2011-01-20 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法
WO2010048670A1 (en) * 2008-10-31 2010-05-06 St Vincent's Hospital Sydney Limited Method of prognosis in chronic kidney disease
EP3590537A1 (en) * 2012-09-26 2020-01-08 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
WO2014100689A1 (en) * 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies

Also Published As

Publication number Publication date
BR112016029820A2 (pt) 2017-10-24
WO2015196145A1 (en) 2015-12-23
EA201790051A1 (ru) 2017-04-28
CA2952032A1 (en) 2015-12-23
US11897948B2 (en) 2024-02-13
JP2017519764A (ja) 2017-07-20
US20170137506A1 (en) 2017-05-18
MX2016016826A (es) 2017-08-28
AU2015276800B2 (en) 2021-03-04
AU2015276800A1 (en) 2017-01-05
EP3157953B1 (en) 2021-12-22
CA2952032C (en) 2023-03-14
US20190292252A1 (en) 2019-09-26
AU2021203523A1 (en) 2021-07-01
EP3157953A1 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
JP6768527B2 (ja) Ｇｄｆ１５調節剤を用いた慢性腎臓病及びその他の腎機能不全の治療
JP7685737B2 (ja) 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
JP6910800B2 (ja) Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
EP3174894B1 (en) Compositions and methods of use for treating metabolic disorders
EP3197493B1 (en) Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
EP3315515A1 (en) Fusion protein containing bdnf
JP2017503022A (ja) インビボで細胞に活性型テロメラーゼを提供する組成物および方法
US20130072441A1 (en) Protease Inhibitors and Preventives or Remedies for Disease
JP6942356B2 (ja) 制御性ｔ細胞の活性化剤及びその使用
EP2970416B1 (en) Methods for treatment of nephrotic syndrome and related conditions
CN107412729A (zh) 用于治疗肾病综合征和有关病症的方法
EP3353196B1 (en) Polypeptides capable of inhibiting the binding between leptin and neuropilin-1
EA042620B1 (ru) Лечение хронического заболевания почек и другого нарушения функции почек при помощи модулятора gdf15
BR112016029820B1 (pt) Uso de um anticorpo anti-gdf15 para a preparação de uma composição e/ou medicamento para no tratamento de doença renal crônica e outras disfunções renais
US8628781B2 (en) Prevention and treatment of cast nephropathy
WO2024011946A1 (en) Polypeptide dimers for the treatment of systemic sclerosis
US20080090766A1 (en) Preventive or therapeutic agents for diseases including interleukin-18 inhibitor as an active ingredient
WO2022092326A1 (ja) 眼組織線維化の阻害に使用するためのｇｄｆ１５調節物質
CA3020339A1 (en) Compositions and methods for treating pancreatitis and pain with death receptor agonists
Bonnet Tumor necrosis factor inhibitors as novel therapeutic tools for vascular remodeling diseases 2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200826

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200923

R150 Certificate of patent or registration of utility model

Ref document number: 6768527

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250